Incidence of Cutaneous T-Cell Lymphoma in the United States, 1973-2002

Criscione, Vincent D.; Weinstock, Martin A.

doi:10.1001/archderm.143.7.854

Cited by 470 publications

(388 citation statements)

References 19 publications

Supporting

Mentioning

338

Contrasting

Unclassified

Order By: Relevance

“…The European Organization for Research and Treatment of Cancer (EORTC) and World Health Organization (WHO) published a consensus classification for cutaneous lymphomas in 2005, as summarized in Table I [2]. In contrast to nodal non-Hodgkin lymphoma, most of which are B-cell derived, 75% of primary cutaneous lymphomas are T-cell derived, two-thirds of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS) [2][3][4]. The incidence of cutaneous T-cell lymphomas (CTCL) has been increasing and is currently 6.4 per million persons, based on Surveillance, Epidemiology, and End Results (SEER) registry data, with the highest incidence rates being reported among males (male:female incidence rate ratio 1.9) and AfricanAmericans (incidence rate ratio 1.5) [3].…”

Section: Disease Overviewmentioning

confidence: 99%

“…In contrast to nodal non-Hodgkin lymphoma, most of which are B-cell derived, 75% of primary cutaneous lymphomas are T-cell derived, two-thirds of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS) [2][3][4]. The incidence of cutaneous T-cell lymphomas (CTCL) has been increasing and is currently 6.4 per million persons, based on Surveillance, Epidemiology, and End Results (SEER) registry data, with the highest incidence rates being reported among males (male:female incidence rate ratio 1.9) and AfricanAmericans (incidence rate ratio 1.5) [3]. While CTCL may occur in children and young adults, this is very uncommon and often associated with histologic variants of MF [5][6][7].…”

Section: Disease Overviewmentioning

confidence: 99%

“…While CTCL may occur in children and young adults, this is very uncommon and often associated with histologic variants of MF [5][6][7]. The incidence of CTCL increases significantly with age, with a median age at diagnosis in the mid-50s and a fourfold increase in incidence appreciated in patients over 70 [3,7].…”

Section: Disease Overviewmentioning

confidence: 99%

See 2 more Smart Citations

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

Section: Disease Overviewmentioning

confidence: 99%

Section: Disease Overviewmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

show abstract

“…The peak age at presentation is in excess of 55 to 60 years [2,3]. There is a male predominance in almost all studies on CTCLs and MF, with a male:female ratio of 1.3:1 to 2:1 [4,5].…”

mentioning

confidence: 99%

Mycosis fungoides as casus pro diagnosi

Borowska¹,

Wasyłyszyn²

2017

Our Dermatol Online

View full text Add to dashboard Cite

“…En los Estados Unidos de Norteamérica entre 2001 y 2005 se estimó una incidencia de 0,8 casos por millón de personas por año, con un rango hombre/ mujer de 2,11 4 . En general es una enfermedad del adulto mayor, ya que existen escasos reportes en menores de 30 años 5 .…”

Section: Enfermedad Recurrente O Refractariaunclassified